AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23118056 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) at 1300 m
Number of subjects: 14
Study 21199271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage sulphonylurea (1-mg glimepiride; Amaryl)
Number of subjects: 274
Study 21199271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 19258083 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 128
Study 19258083 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 128
Study 17216477 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate + Alfacalcidol (group C)
Number of subjects: 90
Study 17216477 — intervention group
Group type: COMPARATOR
Intervention: Alendronate + vitamin D (group B)
Number of subjects: 90
Study 17216477 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (group A)
Number of subjects: 90
Study 15666048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume tumescent liposuction
Number of subjects: 15
Study 12133129 — intervention group
Group type: EXPERIMENTAL
Intervention: Community alcohol prevention programme including server training in responsible beverage service (RBS) and policy initiatives
Number of subjects: 195
Study 12133129 — intervention group
Group type: COMPARATOR
Intervention: Baseline study (1996)
Number of subjects: 195
Study 9475880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lower extremity positive pressure cuffs inflated to 45 Torr during exercise (BLPPex)
Number of subjects: 12
Study 9475880 — intervention group
Group type: COMPARATOR
Intervention: Control group with bilateral lower extremity positive pressure cuffs inflated to 45 Torr during recovery (BLPPrec)
Number of subjects: 12
Study 7890255 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment group with incomplete response
Number of subjects: 0
Study 7890255 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 0
Study 7890255 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with chlamydial genital tract infection
Number of subjects: 0
Study 2254351 — intervention group
Group type: EXPERIMENTAL
Intervention: Prerandomized design
Number of subjects: 0
Study 2254351 — intervention group
Group type: COMPARATOR
Intervention: Classic randomization trial
Number of subjects: 0
Study 28989 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 120
Study 28989 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 120
Study 28989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28989 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam (30 mg)
Number of subjects: 120
Study 28989 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam (15 mg)
Number of subjects: 120
Study 31722937 — intervention group
Group type: EXPERIMENTAL
Intervention: OEND intervention
Number of subjects: 28
Study 31722937 — intervention group
Group type: COMPARATOR
Intervention: Best available standard of care (existing OEND programme)
Number of subjects: 28
Study 29233291 — intervention group
Group type: EXPERIMENTAL
Intervention: Literary fiction reading intervention over eight weeks (n=11)
Number of subjects: 21
Study 29233291 — intervention group
Group type: COMPARATOR
Intervention: Control group not participating in the intervention (n=10)
Number of subjects: 21
Study 29233291 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 21
Study 25029703 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (PRO‐CHO)
Number of subjects: 18
Study 25029703 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate drinks (CHO)
Number of subjects: 18
Study 24130351 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 20
Study 24130351 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C infusion
Number of subjects: 20
Study 24130351 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of GLP-1 and Vitamin C
Number of subjects: 20
Study 24130351 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 20
Study 21360201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (1.25 g kg(‐1), -1°C)
Number of subjects: 10
Study 21360201 — intervention group
Group type: COMPARATOR
Intervention: Warm fluid ingestion (40°C)
Number of subjects: 10
Study 21360201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 10
Study 19961044 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection lumbar plexus and sciatic nerve blocks
Number of subjects: 44
Study 19961044 — intervention group
Group type: COMPARATOR
Intervention: Continuous lumbar plexus and sciatic nerve blocks
Number of subjects: 44
Study 18046188 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (20% maltodextrin at 0.6 g.kg FFM.h)
Number of subjects: 13
Study 18046188 — intervention group
Group type: COMPARATOR
Intervention: Flavored placebo (PLA) drink
Number of subjects: 13
Study 18046188 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation
Number of subjects: 13
Study 15535402 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV drug resistance testing
Number of subjects: 0
Study 15535402 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no resistance testing)
Number of subjects: 0
Study 11685486 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-colloidal albumin (Nanocoll) at concentrations of 10 MBq/microg and higher, prepared under nitrogen and in vacuum.
Number of subjects: 119
Study 9989311 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Toilet Training (ETT)
Number of subjects: 87
Study 9989311 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 87
Study 9989311 — intervention group
Group type: COMPARATOR
Intervention: Intensive Medical Care (IMC)
Number of subjects: 87
Study 7816414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tetrahydrozoline hydrochloride with 0.3% pheniramine maleate
Number of subjects: 10
Study 7816414 — intervention group
Group type: COMPARATOR
Intervention: 0.1% tetrahydrozoline hydrochloride
Number of subjects: 10
Study 7816414 — intervention group
Group type: COMPARATOR
Intervention: 0.3% chlorpheniramine maleate
Number of subjects: 10
Study 31411184 — intervention group
Group type: EXPERIMENTAL
Intervention: Double antithrombotic therapy (DT)
Number of subjects: 9931
Study 31411184 — intervention group
Group type: COMPARATOR
Intervention: Triple antithrombotic therapy (TT)
Number of subjects: 9931
Study 28662460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon SL 0.1mg
Number of subjects: 642
Study 28662460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon SL 0.4mg
Number of subjects: 642
Study 28662460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon SL 0.8mg
Number of subjects: 642
Study 28662460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 25994179 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 171
Study 25994179 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg biweekly (BIW)
Number of subjects: 171
Study 25994179 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg QW/QW
Number of subjects: 171
Study 25994179 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW/QW
Number of subjects: 171
Study 22129348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein at 350 g/kg and lipid at 80 g/kg
Number of subjects: 30
Study 22129348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein at 300 g/kg and lipid at 60 g/kg
Number of subjects: 30
Study 22129348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lipid at 80 g/kg
Number of subjects: 30
Study 22129348 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in dietary lipid for each level of dietary protein
Number of subjects: 30
Study 20598444 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse-related script
Number of subjects: 75
Study 20598444 — intervention group
Group type: COMPARATOR
Intervention: Neutral script
Number of subjects: 75
Study 19694385 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianlie Beixi Capsule
Number of subjects: 240
Study 19694385 — intervention group
Group type: COMPARATOR
Intervention: Control group (compound tablets of zinc and protein)
Number of subjects: 240
Study 16375950 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel‐cisplatin
Number of subjects: 50
Study 16375950 — intervention group
Group type: COMPARATOR
Intervention: docetaxel‐carboplatin
Number of subjects: 50
Study 12720590 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d for 14 weeks followed by 3 mg Cu/d for 8 weeks
Number of subjects: 38
Study 12720590 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 38
Study 12720590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Zn and placebo)
Number of subjects: 38
Study 12720590 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn supplementation
Number of subjects: 38
Study 10972662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (1.5 mg/m2 body surface area)
Number of subjects: 20
Study 10972662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol (1.5 mg/m2 body surface area)
Number of subjects: 20
Study 10972662 — intervention group
Group type: COMPARATOR
Intervention: Control values for Sr absorption (separate group of children with CRF)
Number of subjects: 20
Study 10972662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol and Oral calcitriol
Number of subjects: 20
Study 9076452 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 183
Study 9076452 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 183
Study 8439828 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine initial dose
Number of subjects: 16
Study 8439828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nitrendipine twice daily
Number of subjects: 16
Study 8439828 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine once daily
Number of subjects: 16
Study 8439828 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nitrendipine therapy
Number of subjects: 16
Study 3301560 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg/die for patients <70 kg; 15 mg/die for patients >70 kg)
Number of subjects: 90
Study 3301560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30200895 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard prednisolone plus high-dose mizoribine (10 mg/kg/day once daily for 2 years)
Number of subjects: 0
Study 30200895 — intervention group
Group type: COMPARATOR
Intervention: Standard prednisolone alone
Number of subjects: 0
Study 27456976 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help CBTv (12-week intervention with eight therapist support sessions)
Number of subjects: 30
Study 27456976 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 30
Study 23918230 — intervention group
Group type: EXPERIMENTAL
Intervention: Justice violation condition (experimenter negligence)
Number of subjects: 0
Study 23918230 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard protocol)
Number of subjects: 0
Study 23918230 — intervention group
Group type: EXPERIMENTAL
Intervention: Negligence/justice violation condition
Number of subjects: 0
Study 21740624 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help programme with extensive email support
Number of subjects: 376
Study 21740624 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help programme with minimal email support
Number of subjects: 376
Study 21740624 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 376
Study 20204925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical with CE (HE)
Number of subjects: 0
Study 20204925 — intervention group
Group type: EXPERIMENTAL
Intervention: Real (R)
Number of subjects: 0
Study 20204925 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical (H)
Number of subjects: 0
Study 18378568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/d
Number of subjects: 243
Study 18378568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 15709986 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg once daily
Number of subjects: 110
Study 15709986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11833025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual tasks (simultaneous cognitive tasks)
Number of subjects: 23
Study 11833025 — intervention group
Group type: COMPARATOR
Intervention: Single tasks (motor and cognitive performances)
Number of subjects: 23
Study 10341672 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal (0.2 g/kg body weight; mean 14 g)
Number of subjects: 0
Study 10341672 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal (0.6 g/kg body weight; mean 43 g)
Number of subjects: 0
Study 10341672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals (Low-fat and High-fat)
Number of subjects: 0
Study 7776772 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (three fractions of 8 Gy or 9 Gy in 8 days)
Number of subjects: 70
Study 7776772 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by hyperthermia (43 degrees C for 60 min)
Number of subjects: 70
Study 7776772 — intervention group
Group type: COMPARATOR
Intervention: Radiation dose of 24 Gy
Number of subjects: 70
Study 7776772 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose of 27 Gy
Number of subjects: 70
Study 7776772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Number of subjects: 70
Study 7776772 — intervention group
Group type: COMPARATOR
Intervention: Tumour size ≤ 4 cm
Number of subjects: 70
Study 7776772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour size > 4 cm
Number of subjects: 70
Study 7776772 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall 5-year survival rate
Number of subjects: 70
Study 2261306 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 100
Study 2261306 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 100
Study 371597 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.1%
Number of subjects: 0
Study 371597 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.25%
Number of subjects: 0
Study 371597 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 0
Study 371597 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 1.0%
Number of subjects: 0
Study 371597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30844995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring use with counseling and social support intervention
Number of subjects: 2585
Study 30844995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring use without worries
Number of subjects: 2585
Study 30844995 — intervention group
Group type: COMPARATOR
Intervention: Dapivirine vaginal ring use after intervention
Number of subjects: 2585
Study 28756438 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 50
Study 28756438 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 50
Study 28756438 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 26209502 — intervention group
Group type: COMPARATOR
Intervention: AS + RT
Number of subjects: 397
Study 26209502 — intervention group
Group type: EXPERIMENTAL
Intervention: AS + RT + CT
Number of subjects: 397
Study 24327333 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FAC (fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 126
Study 24327333 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 126
Study 24327333 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FAC
Number of subjects: 126
Study 24327333 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant CMF
Number of subjects: 126
Study 24327333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (FAC and CMF)
Number of subjects: 126
Study 24327333 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 126
Study 24327333 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 126
Study 24327333 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of pathologically involved lymph nodes (pLN)
Number of subjects: 126
Study 23014489 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) foods (80 g/d)
Number of subjects: 83
Study 23014489 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain (RG) foods (0 g/d)
Number of subjects: 83
Study 23014489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WG and RG foods
Number of subjects: 83
Study 19954479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (RT) twice a week for a total of ten treatments, along with high-dose supplementation of zinc and vitamins A, E, and beta-carotene.
Number of subjects: 7
Study 19954479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (RT) after the fifth treatment.
Number of subjects: 7
Study 19954479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (RT) compared to before RT at time 1 and time 2.
Number of subjects: 7
Study 17678776 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with propofol target-controlled infusion
Number of subjects: 60
Study 17678776 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil with propofol target-controlled infusion
Number of subjects: 60
Study 17678776 — intervention group
Group type: COMPARATOR
Intervention: High-dose remifentanil with propofol target-controlled infusion
Number of subjects: 60
Study 17678776 — intervention group
Group type: COMPARATOR
Intervention: Low-dose remifentanil with propofol target-controlled infusion
Number of subjects: 60
Study 15181127 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-ECD SPECT in IPD patients
Number of subjects: 140
Study 15181127 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-ECD SPECT in MSA patients
Number of subjects: 140
Study 15181127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist dosage in PD patients
Number of subjects: 140
Study 15181127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance in relation to limbic perfusion
Number of subjects: 140
Study 11813898 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau time of 1 ms
Number of subjects: 26
Study 11813898 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau time of 2 ms
Number of subjects: 26
Study 11813898 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau time of 5 ms
Number of subjects: 26
Study 11813898 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau time of 10 ms
Number of subjects: 26
Study 9264355 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase mammograms in women who ever used estrogen
Number of subjects: 8887
Study 9264355 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase mammograms in women who ever used estrogen
Number of subjects: 8887
Study 9264355 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase mammograms in never-users of estrogen
Number of subjects: 8887
Study 9264355 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase mammograms in never-users of estrogen
Number of subjects: 8887
Study 8510911 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTPAC
Number of subjects: 30
Study 8510911 — intervention group
Group type: COMPARATOR
Intervention: Standard full-threshold 4-2-dB double-staircase strategy
Number of subjects: 30
Study 3481318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg (twice daily)
Number of subjects: 12
Study 3481318 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg (twice daily)
Number of subjects: 12
Study 3481318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg (twice daily)
Number of subjects: 12
Study 30202041 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional hierarchical mixture models for SNP analysis
Number of subjects: 0
Study 30102787 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassionate letter-writing intervention
Number of subjects: 40
Study 30102787 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 40
Study 27184586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated self-expanding Axxess™ biolimus-eluting bifurcation stent in the proximal main vessel and additional Absorb™ everolimus-eluting BRS in the branches
Number of subjects: 60
Study 27184586 — intervention group
Group type: COMPARATOR
Intervention: Modified T technique using Absorb™ only
Number of subjects: 60
Study 24701541 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium microimplants (Group A)
Number of subjects: 20
Study 24701541 — intervention group
Group type: COMPARATOR
Intervention: Conventional molar anchorage (Group B)
Number of subjects: 20
Study 22342916 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018 ISS vaccine
Number of subjects: 0
Study 22342916 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B(®) (licensed hepatitis B vaccine)
Number of subjects: 0
Study 21047593 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA screening with a cut-off of 4 ng/ml
Number of subjects: 56294
Study 21047593 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA screening with a cut-off of 3 ng/ml
Number of subjects: 56294
Study 21047593 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced prostate cancer detection
Number of subjects: 56294
Study 21047593 — intervention group
Group type: EXPERIMENTAL
Intervention: Second screening round
Number of subjects: 56294
Study 21047593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 56294
Study 17548243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg once per day
Number of subjects: 189